View in EDS

Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell Carcinoma.

Saved in:
Bibliographic Details
Title: Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell Carcinoma.
Authors: Mullangi S; University of Kansas Medical Center, Kansas City, Kansas., Lekkala MR; The University of Kansas Cancer Center, Kansas City, Kansas., Blocker S; The University of Kansas Cancer Center, Kansas City, Kansas., Kim D; The University of Kansas Cancer Center, Kansas City, Kansas., Zhang J; The University of Kansas Cancer Center, Kansas City, Kansas., Huang C; The University of Kansas Cancer Center, Kansas City, Kansas., Neupane P; The University of Kansas Cancer Center, Kansas City, Kansas., Li H; The University of Kansas Cancer Center, Kansas City, Kansas., Schieber T; The University of Kansas Cancer Center, Kansas City, Kansas.
Source: JTO clinical and research reports [JTO Clin Res Rep] 2025 Jul 03; Vol. 6 (11), pp. 100875. Date of Electronic Publication: 2025 Jul 03 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41245307
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell Carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Mullangi+S%22">Mullangi S</searchLink>; University of Kansas Medical Center, Kansas City, Kansas.<br /><searchLink fieldCode="AU" term="%22Lekkala+MR%22">Lekkala MR</searchLink>; The University of Kansas Cancer Center, Kansas City, Kansas.<br /><searchLink fieldCode="AU" term="%22Blocker+S%22">Blocker S</searchLink>; The University of Kansas Cancer Center, Kansas City, Kansas.<br /><searchLink fieldCode="AU" term="%22Kim+D%22">Kim D</searchLink>; The University of Kansas Cancer Center, Kansas City, Kansas.<br /><searchLink fieldCode="AU" term="%22Zhang+J%22">Zhang J</searchLink>; The University of Kansas Cancer Center, Kansas City, Kansas.<br /><searchLink fieldCode="AU" term="%22Huang+C%22">Huang C</searchLink>; The University of Kansas Cancer Center, Kansas City, Kansas.<br /><searchLink fieldCode="AU" term="%22Neupane+P%22">Neupane P</searchLink>; The University of Kansas Cancer Center, Kansas City, Kansas.<br /><searchLink fieldCode="AU" term="%22Li+H%22">Li H</searchLink>; The University of Kansas Cancer Center, Kansas City, Kansas.<br /><searchLink fieldCode="AU" term="%22Schieber+T%22">Schieber T</searchLink>; The University of Kansas Cancer Center, Kansas City, Kansas.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101769967%22">JTO clinical and research reports</searchLink> [JTO Clin Res Rep] 2025 Jul 03; Vol. 6 (11), pp. 100875. <i>Date of Electronic Publication: </i>2025 Jul 03 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%22">Elsevier Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101769967 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-3643 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226663643%22">26663643 </searchLink><i>NLM ISO Abbreviation: </i>JTO Clin Res Rep <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41245307
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jtocrr.2025.100875
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100875
    Titles:
      – TitleFull: Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell Carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mullangi S
      – PersonEntity:
          Name:
            NameFull: Lekkala MR
      – PersonEntity:
          Name:
            NameFull: Blocker S
      – PersonEntity:
          Name:
            NameFull: Kim D
      – PersonEntity:
          Name:
            NameFull: Zhang J
      – PersonEntity:
          Name:
            NameFull: Huang C
      – PersonEntity:
          Name:
            NameFull: Neupane P
      – PersonEntity:
          Name:
            NameFull: Li H
      – PersonEntity:
          Name:
            NameFull: Schieber T
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 03
              M: 07
              Text: 2025 Jul 03
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2666-3643
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: JTO clinical and research reports
              Type: main
ResultId 1